- Home
- SOGP vs SNOA Comparison
SOGP vs SNOA Comparison
Compare SOGP & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- SNOA
- Stock Information
- Founded
- SOGP 2010
- SNOA 1999
- Country
- SOGP Singapore
- SNOA United States
- Employees
- SOGP N/A
- SNOA N/A
- Industry
- SOGP
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- SOGP
- SNOA Health Care
- Exchange
- SOGP NYSE
- SNOA Nasdaq
- Market Cap
- SOGP 6.9M
- SNOA 6.4M
- IPO Year
- SOGP 2020
- SNOA 2007
- Fundamental
- Price
- SOGP $1.33
- SNOA $3.32
- Analyst Decision
- SOGP
- SNOA
- Analyst Count
- SOGP 0
- SNOA 0
- Target Price
- SOGP N/A
- SNOA N/A
- AVG Volume (30 Days)
- SOGP 10.2K
- SNOA 60.2K
- Earning Date
- SOGP 06-17-2025
- SNOA 06-16-2025
- Dividend Yield
- SOGP N/A
- SNOA N/A
- EPS Growth
- SOGP N/A
- SNOA N/A
- EPS
- SOGP N/A
- SNOA N/A
- Revenue
- SOGP $278,363,908.00
- SNOA $13,973,000.00
- Revenue This Year
- SOGP $48.88
- SNOA $23.89
- Revenue Next Year
- SOGP N/A
- SNOA $25.45
- P/E Ratio
- SOGP N/A
- SNOA N/A
- Revenue Growth
- SOGP N/A
- SNOA 13.51
- 52 Week Low
- SOGP $1.18
- SNOA $1.75
- 52 Week High
- SOGP $2.58
- SNOA $9.37
- Technical
- Relative Strength Index (RSI)
- SOGP 43.20
- SNOA 52.15
- Support Level
- SOGP $1.20
- SNOA $3.05
- Resistance Level
- SOGP $1.32
- SNOA $3.60
- Average True Range (ATR)
- SOGP 0.06
- SNOA 0.19
- MACD
- SOGP 0.04
- SNOA -0.01
- Stochastic Oscillator
- SOGP 85.14
- SNOA 49.09
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.